IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Klaus-Helmut Mohrs

USPTO Granted Patents = 24

Average Co-Inventor Count = 6.4

ph-index = 7

Forward Citations = 179(Granted Patents)


Company Filing History:

goldMedal23 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
silverMedal1 out of 38 
 
Bayeraktiengesellschaft
 patents

Years Active: 1991-2004

Loading Chart...
24 patents (USPTO):
1. 6727279 - Arylsulphonamides and analogues (2004-04-27),
2. 6573278 - Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases (2003-06-03),
3. 6469054 - Aryl sulphonamides and analogues (2002-10-22),
4. 6262112 - Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases (2001-07-17),
5. 5962724 - High enantio-selective process for producing pure enantiomeric (1999-10-05),
6. 5693650 - 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives (1997-12-02),
7. 5691337 - Oxy-phenyl-(phenyl)glycinolamides with heterocyclic substituents (1997-11-25),
8. 5646162 - Oxy-phenyl-(phenyl)glycinolamides with heterocyclic substituents (1997-07-08),
9. 5597833 - Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives (1997-01-28),
10. 5504213 - Benzofuranyl-and-thiophenyl-alkanecarboxyclic acid derivatives (1996-04-02),
11. 5473076 - Enantiomerically pure intermediates for (quinolin-2-yl-methoxy) (1995-12-05),
12. 5399698 - Quinolin-2-yl-methoxybenzylhydroxyureas (1995-03-21),
13. 5391747 - Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and (1995-02-21),
14. 5310744 - Quinolylmethoxyphenyl-acetamides (1994-05-10),
15. 5306820 - Process for the preparation of enantiomerically pure substituted (1994-04-26),

Title: Klaus-Helmut Mohrs: Pioneering Innovator in Neurodegenerative Disorder Treatments

Introduction:

Klaus-Helmut Mohrs, a visionary inventor hailing from Wuppertal, Germany, is a beacon of innovation, inspiring countless inventors to think outside the box and pursue their creative ideas. With an impressive portfolio of 24 patents, Mohrs has made significant contributions to the field of neurodegenerative disorder treatments.

Latest Patents:

Mohrs' latest patents showcase his dedication to advancing medical treatments. His inventions include novel arylsulphonamides and analogues, which are utilized in the prophylaxis and treatment of neurodegenerative disorders such as cerebral apoplexy, craniocerebral trauma, pain, and spasticity. Additionally, Mohrs has developed aryl ether sulphonamides for the treatment of neurodegenerative diseases, further highlighting his commitment to improving healthcare outcomes.

Career Highlights:

Throughout his illustrious career, Klaus-Helmut Mohrs has been associated with renowned companies such as Bayer Aktiengesellschaft, where he has left a lasting impact through his innovative work in pharmaceuticals. His expertise and groundbreaking inventions have positioned him as a trailblazer in the field of medical innovation, with a focus on enhancing the quality of life for individuals affected by neurodegenerative disorders.

Collaborations:

Mohrs' collaborative efforts with esteemed colleagues such as Siegfried Raddatz and Michael Matzke have been instrumental in shaping his inventive endeavors. Together, they have worked tirelessly to push the boundaries of medical science and develop cutting-edge solutions that address the complex challenges associated with neurodegenerative diseases.

Conclusion:

In conclusion, Klaus-Helmut Mohrs stands as a testament to the power of innovation and perseverance in driving positive change in society. His transformative inventions in the realm of neurodegenerative disorder treatments serve as a source of inspiration for future generations of inventors, encouraging them to explore new possibilities and make a lasting impact on the world.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…